Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
YUKAWA is a 12-week, randomized, double-blind, placebo-controlled, phase 2 study evaluating
the efficacy and safety of evolocumab (AMG 145) in statin-treated Japanese patients
at high cardiovascular risk.